select a format

Single User License
USD 10995 INR 708628
Site License
USD 21990 INR 1417256
Corporate User License
USD 32985 INR 2125883

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


PharmaPoint: HER2-Negative Breast Cancer-Global Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Negative Breast Cancer-Global Drug Forecast and Market Analysis to 2023


  • Products Id :- GDHC92PIDR
  • |
  • Pages: 360
  • |
  • January 2015
  • |
  • |
  Request for Sample Report

Executive Summary

PharmaPoint: HER2-Negative Breast Cancer-Global Drug Forecast and Market Analysis to 2023

Breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-negative breast cancer market, with coverage of multiple settings; neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic.

Overall five year survival in breast cancer is relatively high, at around 90%, but this is subjective to the subtype and stage of the disease. Importantly this report segments HER2 negative breast cancer into its two major subtypes; hormone receptor positive (HR+) and triple negative breast cancer (TNBC).

HR+ disease accounts for around 90% of all HER2 negative breast cancers. It responds well to hormonal agents such tamoxifen and the 3rd generation aromatase inhibitors. The advent of hormonal therapy has alleviated some of the unmet needs for these patients, however opportunities still remain. The pipeline for the HR+ market is very strong, with several exciting new agents such as the PI3K and CDK 4/6 inhibitors. GlobalData believes these will have a phenomenal effect on the treatment paradigm for patients with the disease and address many of the unmet needs which patients currently face.

TNBC accounts for around 10% of all HER2 negative breast cancers. TNBC does not respond to hormonal agents and few chemotherapies have been shown to work effectively at managing the disease. The level of unmet need for patients with this form of the disease is very high; furthermore around 30% of TNBC patients will carry a BRCA mutation- these patients have an even worse outcome, with an ultra-high degree of unmet needs. The pipeline for the TNBC market exclusive of the BRCA population is non-existent. However in regards to the BRCA mutation positive market, huge changes are to occur which could potentially redefine the way these patients are treated. This will be chiefly due to the entrance of several PARP inhibitors in the market.

Highlights

Key Questions Answered

How is the disease management evolving? What is the impact for drug manufacturers?

What are the R&D strategies being used by drug makers?

What opportunities remain for future players?

How large are the neoadjuvant, adjuvant, and metastatic markets for TNBC and HR+ breast cancer?

What exciting, innovative approaches are being investigated in HER2-negative breast cancer?

What to KOLs think about the latest therapies and drug development strategies?

Key Findings

The HER2-negative breast cancer market will increase by 4-fold; from USD 1.45 billion in 2013 to USD 6.12 billion in 2023 at a CAGR of 15.5%. Growth will be driven by the rapid uptake of new premium priced agents in both the HR+ and TNBC settings. Presently the HR + and TNBC settings have around an equal share of the HER2 negative market, by 2023 this is expected to change drastically to around 80% and 20% respectively.

In the HR+ setting, the launch of a number of innovative premium-priced products namely, the PI3K and CDK 4/6 inhibitors, will act as the main drivers for growth. The collective sales from these agents alone will account for USD 3.6 billion and 79% of the global sales in the HR+ setting in 2023. GlobalData expects Pfizer's Palbociclib to capture sales of USD 1.85 billion in 2023, making it the highest grossing drug in the HR+ setting and HER2 negative breast cancer as a whole.

In the TNBC setting, the launch of several PARP inhibitors will act as the main drivers for growth. The collective sales from all of the PARP inhibitors will account for USD 1.02 billion and 94% of the global sales in the TNBC setting in 2023. Chief amongst them will be AstraZeneca's Lynparza which will capture sales of USD 926.3m in 2023.

By 2023, the adjuvant setting will prove to be the most lucrative setting in both HR+ and TNBC. Galena Biopharma's NeuVax (nelipepimut-S/E75) will enter the adjuvant setting (HR+) in the US and 5EU; even with relatively low patient shares (<10%), it will score comparatively high global sales of USD 567m by 2023. AstraZeneca's Lynparza will also enter the adjuvant setting (TNBC), indeed the vast majority of its 2023 sales are expected to come from here 79%; USD 731m.

Scope

Overview of HER2-negative breast cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized HER2-negative breast cancer therapeutics market revenue, cost of therapy, and treatment usage patterns in 15 patient segments, forecast from 2013 to 2023.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the HER2-negative breast cancer therapeutics market

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidates in Phase III development are profiled.

Analysis of the current and future market competition in the global HER2-negative breast cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons To Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global HER2-negative breast cancer therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HER2-negative breast cancer therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

1 Table of Contents

1 Table of Contents 10

1.1 List of Tables 17

1.2 List of Figures 23

2 Introduction 26

2.1 Catalyst 26

2.2 Related Reports 27

2.3 Upcoming Related Reports 27

3 Disease Overview 28

3.1 Etiology and Pathophysiology 28

3.1.1 Etiology 28

3.1.2 Pathophysiology 29

3.1.3 Basic Breast Anatomy 30

3.2 Disease Classification/Staging Systems 31

3.3 Symptoms 33

3.4 Prognosis 33

3.5 Quality of Life 34

4 Epidemiology 37

4.1 Disease Background 37

4.2 Risk Factors and Comorbidities 37

4.2.1 A family history of breast cancer and BRCA1/2 gene mutations significantly increase the breast cancer risk 39

4.2.2 Reproductive hormonal factors influence the risk of breast cancer 39

4.2.3 Modifiable lifestyle-related factors increase the risk of mortality in breast cancer patients 41

4.2.4 Screening programs have been shown to reduce breast cancer mortality, although the benefits need to be carefully weighed against the risks 43

4.3 Global Trends 46

4.3.1 Incidence 46

4.3.2 Prevalence and Survival 52

4.4 Forecast Methodology 56

4.4.1 Sources Used 58

4.4.2 Sources Not Used 62

4.4.3 Forecast Assumptions and Methods 63

4.5 Epidemiological Forecast for Breast Cancer (2013-2023)-Diagnosed Incident Cases 66

4.5.1 Diagnosed Incident Cases of Breast Cancer 66

4.5.2 Diagnosed Incident Cases of Breast Cancer by Age 68

4.5.3 Diagnosed Incident Cases of Breast Cancer by Menopausal Status 70

4.5.4 Diagnosed Incident Cases of Breast Cancer Segmented by Stage at Diagnosis 72

4.5.5 Age-Standardized Diagnosed Incidence Rate of Breast Cancer 73

4.6 Epidemiological Forecast for Breast Cancer (2013-2023) Diagnosed Prevalent Cases 74

4.6.1 Five-Year Diagnosed Prevalent Cases of Breast Cancer 74

4.6.2 Five-Year Diagnosed Prevalent Cases by Menopausal Status 76

4.6.3 Five-Year Diagnosed Prevalent Cases by Hormone Receptor Subtypes 77

4.7 Discussion 79

4.7.1 Epidemiological Forecast Insight 79

4.7.2 Limitations of the Analysis 81

4.7.3 Strengths of the Analysis 82

5 Disease Management 84

5.1 Diagnosis and Treatment Overview 84

5.1.1 Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB) 84

5.1.2 Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIC) 86

5.1.3 Treatment Guidelines and Leading Prescribed Drugs 90

5.2 US 91

5.2.1 Diagnosis 91

5.2.2 Clinical Practice 92

5.3 France 95

5.3.1 Diagnosis 95

5.3.2 Clinical Practice 96

5.4 Germany 99

5.4.1 Diagnosis 99

5.4.2 Clinical Practice 100

5.5 Italy 103

5.5.1 Diagnosis 103

5.5.2 Clinical Practice 104

5.6 Spain 106

5.6.1 Diagnosis 106

5.6.2 Clinical Practice 107

5.7 UK 110

5.7.1 Diagnosis 110

5.7.2 Clinical Practice 111

5.8 Japan 114

5.8.1 Diagnosis 114

5.8.2 Clinical Practice 115

5.9 China 117

5.9.1 Diagnosis 117

5.9.2 Clinical Practice 119

6 Competitive Assessment 122

6.1 Overview 122

6.2 Product Profiles (Branded Therapies) 123

6.2.1 Abraxane (nab-paclitaxel) 123

6.2.2 Afinitor (everolimus) 128

6.2.3 Avastin (bevacizumab) 133

6.2.4 Doxil/Caelyx (pegylated liposomal doxorubicin) 137

6.2.5 Halaven (eribulin mesylate) 142

6.2.6 Ixempra (ixabepilone) 145

6.2.7 Xeloda (capecitabine) 148

6.3 Product Profiles (Hormonal Agents) 151

6.3.1 Tamoxifen 151

6.3.2 Faslodex (fulvestrant) 151

6.3.3 Aromatase Inhibitors 152

7 Unmet Need and Opportunity 156

7.1 Overview 156

7.1.1 Defined treatment plan for BRCA mutation-positive patients and prevention of prophylactic surgeries 158

7.1.2 Specific treatment options for TNBC patients 160

7.1.3 Prevention of brain metastasis 161

7.1.4 Neoadjuvant therapy that can downstage tumors 163

7.1.5 For HR+patients, reduced resistance to hormonal agents 164

7.1.6 Improved convenience of administration of hormonal agents 166

8 Pipeline Assessment 168

8.1 Overview 168

8.1.1 Abemaciclib (LY2835219) 169

8.1.2 Buparlisib (BKM- 120) 175

8.1.3 Javlor (vinflunine) 181

8.1.4 LEE011 185

8.1.5 NeuVax (nelipepimut-S/E75) 190

8.1.6 Niraparib (MK4827) 195

8.1.7 NKTR- 102 (etirinotecan pegol) 200

8.1.8 Lynparza (olaparib) 204

8.1.9 Palbociclib (PD-0332991) 209

8.1.10 Talazoparib (BMN 673) 215

8.1.11 Veliparib (ABT-888) 219

8.2 Promising Drugs in Clinical Development 224

8.2.1 PD-/PD-L 1 Immunotherapies 225

9 Current and Future Players 227

9.1 Overview 227

9.2 Trends in Corporate Strategy 229

9.3 Company Profiles 232

9.3.1 AstraZeneca 232

9.3.2 Bristol-Myers Squibb 233

9.3.3 Eli Lilly 235

9.3.4 Pfizer 236

9.3.5 Novartis/GlaxoSmithKline 239

10 Market Outlook 241

10.1 Global Markets 241

10.1.1 Forecast 241

10.1.2 Drivers and Barriers-Global Issues 247

10.2 US 249

10.2.1 Forecast 249

10.2.2 Key Events 252

10.2.3 Drivers and Barriers 253

10.3 France 255

10.3.1 Forecast 255

10.3.2 Key Events 258

10.3.3 Drivers and Barriers 259

10.4 Germany 260

10.4.1 Forecast 260

10.4.2 Key Events 264

10.4.3 Drivers and Barriers 265

10.5 Italy 266

10.5.1 Forecast 266

10.5.2 Key Events 270

10.5.3 Drivers and Barriers 271

10.6 Spain 272

10.6.1 Forecast 272

10.6.2 Key Events 275

10.6.3 Drivers and Barriers 276

10.7 UK 277

10.7.1 Forecast 277

10.7.2 Key Events 281

10.7.3 Drivers and Barriers 282

10.8 Japan 284

10.8.1 Forecast 284

10.8.2 Key Events 287

10.8.3 Drivers and Barriers 288

10.9 China 289

10.9.1 Forecast 289

10.9.2 Key Events 292

10.9.3 Drivers and Barriers 292

11 Appendix 294

11.1 Bibliography 294

11.2 Abbreviations 321

11.3 Methodology 329

11.4 Forecasting Methodology 329

11.4.1 Diagnosed HER2-Negative Breast Cancer Patients 329

11.4.2 Percentage of Drug-Treated Patients 330

11.4.3 Drugs Included in Each Therapeutic Class 330

11.4.4 Launch and Patent Expiry Dates 331

11.4.5 General Pricing Assumptions 332

11.4.6 Individual Drug Assumptions 334

11.4.7 Generic Erosion 342

11.4.8 Pricing of Pipeline Agents 342

11.5 Primary Research-KOLs Interviewed for This Report 353

11.6 Primary Research-High-Prescriber Survey 355

11.7 About the Authors 356

11.7.1 Analyst 356

11.7.2 Director of Oncology 356

11.7.3 Epidemiologist 357

11.7.4 Director of Epidemiology 357

11.7.5 Global Head of Healthcare 358

11.8 About GlobalData 359

11.9 Disclaimer 359

1.2 List of Figures

Figure 1: Basic Breast Anatomy, Including Key Lymph Nodes 31

Figure 2: 8MM, Age-Standardized Incidence Rate of Breast Cancer, Ages ?15 Years, Women, Cases per 100,000 Population, 2008 46

Figure 3: 8MM, Incidence Rate of Breast Cancer, Ages ?15 Years, Women, Rate per 100,000 Population, 2008 47

Figure 4: US, Incidence Rate of Breast Cancer, All Ages, Women, Cases per 100,000 Population, 1975-2009 48

Figure 5: 5EU, Incidence Rate of Breast Cancer, Ages ?15 Years, Women, Cases per 100,000 Population, 1975-2010 50

Figure 6: Japan, Incidence Rate of Breast Cancer, All Ages, Women, Cases per 100,000 Population, 2003-2008 51

Figure 7: 8MM, Relative Survival Rate for Breast Cancer, All Ages*, Women, %, 1991-2004** 53

Figure 8: 8MM, Diagnosed Incident Cases of Breast Cancer, Ages ?20 Years, Women, N, 2013-2023 68

Figure 9: 8MM, Diagnosed Incident Cases of Breast Cancer, by Age, Women, N, 2013 70

Figure 10: 8MM, Diagnosed Incident Cases of Breast Cancer by Menopausal Status, Ages ?20 Years, Women, N, 2013 71

Figure 11: 8MM, Diagnosed Incident Cases of Breast Cancer by Stage at Diagnosis, Ages ?20 Years, Women, N, 2013 73

Figure 12: 8MM, Age-Standardized Diagnosed Incidence Rate of Breast Cancer, Ages ?20 Years, Women, Cases per 100,000 Population, 2013 74

Figure 13: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer, Ages ?20 Years, Women, N, 2013-2023 76

Figure 14: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer by Menopausal Status, Ages ?20 Years, Women, N, 2013 77

Figure 15: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer by Hormone Receptor Subtypes, Ages ?20 Years, Women, N, 2013 79

Figure 16: Key Late-Stage Clinical Trials of Abraxane 124

Figure 17: Key Late-Stage Clinical Trials of Afinitor 129

Figure 18: Key Late-Stage Clinical Trials of Avastin 134

Figure 19: Key Late-Stage Clinical Trials of Halaven 142

Figure 20: Late Stage Clinical Trials of Drugs in HR+ Breast Cancer 170

Figure 21: Late Stage Clinical Trials of Drugs in TNBC 171

Figure 22: Key Late-Stage Clinical Trials of Abemaciclib 171

Figure 23: Clinical and Commercial Positioning of Abemaciclib 173

Figure 24: Key Late-Stage Clinical Trials of Buparlisib 177

Figure 25: Clinical and Commercial Positioning of Buparlisib 179

Figure 26: Key Late-Stage Clinical Trials of Javlor 182

Figure 27: Clinical and Commercial Positioning of Javlor 183

Figure 28: Key Late-Stage Clinical Trials of LEE011 187

Figure 29: Clinical and Commercial Positioning of LEE011 188

Figure 30: Key Late-Stage Clinical Trials of NeuVax 192

Figure 31: Clinical and Commercial Positioning of NeuVax 194

Figure 32: Key Late-Stage Clinical Trials of Niraparib 196

Figure 33: Clinical and Commercial Positioning of Niraparib 198

Figure 34: Key Late-Stage Clinical Trials of NKTR-102 201

Figure 35: Clinical and Commercial Positioning of NKTR-102 202

Figure 36: Key Late-Stage Clinical Trials of Lynparza 205

Figure 37: Clinical and Commercial Positioning of Lynparza 207

Figure 38: Key Late-Stage Key Clinical Trials of Palbociclib 210

Figure 39: Clinical and Commercial Positioning of Palbociclib 213

Figure 40: Key Late-Stage Clinical Trials of Talazoparib 216

Figure 41: Clinical and Commercial Positioning of Talazoparib 218

Figure 42: Key Late-Stage Clinical Trials of Veliparib 220

Figure 43: Clinical and Commercial Positioning of Veliparib 222

Figure 44: Global Sales (USD m) of Branded Products for HER2-Negative Breast Cancer by Company*, 2013-2023 228

Figure 45: Company Portfolio Gap Analysis in HER2-Negative Breast Cancer 2013-2023 229

Figure 46: Global Sales (USD m) for HER2-Negative Breast Cancer by Region, 2013-2023 245

Figure 47: Global Sales for HER2-Negative Breast Cancer by Drug, 2013-2022 246

Figure 48: Sales for HER2-Negative Breast Cancer in the US by Drug, 2013-2022 251

Figure 49: Sales for HER2-Negative Breast Cancer in France by Drug, 2013-2023 257

Figure 50: Sales for HER2-Negative Breast Cancer in Germany by Drug, 2013-2023 263

Figure 51: Sales for HER2-Negative Breast Cancer in Italy by Drug, 2013-2023 269

Figure 52: Sales for HER2-Negative Breast Cancer in Spain by Drug, 2013-2022 274

Figure 53: Sales for HER2-Negative Breast Cancer in the UK by Drug, 2013-2023 280

Figure 54: Sales for HER2-Negative Breast Cancer in Japan by Drug, 2013-2023 286

Figure 55: Sales for HER20Negative Breast Cancer in China by Drug, 2013-2023 291

1.1 List of Tables

Table 1: AJCC Stage Definitions for Breast Cancer 32

Table 2: Prognosis for Breast Cancer 33

Table 3: Selected Major Risk Factors and Comorbidities for Breast Cancer 38

Table 4: Breast Cancer Mortality Attributable to Lifestyle-Related Risk Factors 42

Table 5: 8MM, Current Status and Plans of Large-Scale Breast Cancer Screening Programs 45

Table 6: 8MM, Relative Survival Rate for Breast Cancer, All Ages*, Women, %, 1991-2004** 53

Table 7: Conversion of Common Staging Systems for Breast Cancer Used in the Forecast 57

Table 8: 8MM, Sources of the Breast Cancer Diagnosed Incidence Data Used in the Epidemiological Forecast 57

Table 9: 8MM, Diagnosed Incident Cases of Breast Cancer, Ages ?20 Years, Women, N, 2013-2023 67

Table 10: 8MM, Diagnosed Incident Cases of Breast Cancer by Age, Women, N (Row %), 2013 69

Table 11: 8MM, Diagnosed Incident Cases of Breast Cancer by Menopausal Status, Ages ?20 Years, Women, N (Row %), 2013 71

Table 12: 8MM, Diagnosed Incident Cases of Breast Cancer by Stage at Diagnosis, Ages ?20 Years, Women, N, 2013 72

Table 13: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer, Ages ?20 Years, Women, N, 2013-2023 75

Table 14: 8MM, Five-Year Diagnosed Prevalent Cases of Breast Cancer by Hormone Receptor Subtypes, Ages ?20 Years, Women, N, 2013 78

Table 15: Treatment Guidelines for HER2-Negative Breast Cancer 90

Table 16: Most Prescribed Regimens for HER2-Negative Breast Cancer by Drug Class in the Global Markets, 2013 91

Table 17: HER2-Negative Breast Cancer Diagnosis and Treatment, Country Profile-US 92

Table 18: HER2-Negative Breast Cancer Diagnosis and Treatment, Country Profile-France 96

Table 19: HER2-Negative Breast Cancer Diagnosis and Treatment, Country Profile-Germany 100

Table 20: HER2-Negative Breast Cancer Diagnosis and Treatment, Country Profile-Italy 104

Table 21: HER2-Negative Breast Cancer Diagnosis and Treatment, Country Profile-Spain 107

Table 22: HER2-Negative Breast Cancer Diagnosis and Treatment, Country Profile-UK 111

Table 23: HER2-Negative Breast Cancer Diagnosis and Treatment Country Profile-Japan 115

Table 24: HER2-Negative Breast Cancer Diagnosis and Treatment, Country Profile-China 119

Table 25: Product Profile-Abraxane 125

Table 26: Abraxane SWOT Analysis, 2013 127

Table 27: Global Sales Forecast (USD m) for Abraxane, 2013-2023 128

Table 28: Product Profile-Afinitor (everolimus) 130

Table 29: Afinitor SWOT Analysis, 2013 131

Table 30: Global Sales Forecast (USD m) for Afinitor, 2013-2023 132

Table 31: Product Profile-Avastin 134

Table 32: Avastin SWOT Analysis, 2013 136

Table 33 Global Sales Forecast (USD m) for Avastin, 2013-2023 137

Table 34: Product Profile-Doxil 139

Table 35: Doxil SWOT Analysis, 2013 141

Table 36: Global Sales Forecast (USD m) for Doxil/Caelyx, 2013-2023 141

Table 37: Product Profile-Halavan 143

Table 38: Halaven SWOT Analysis, 2013 144

Table 39: Global Sales Forecast (USD m) for Halaven, 2013-2023 145

Table 40: Product Profile-Ixempra 146

Table 41: Ixempra SWOT Analysis, 2013 147

Table 42: Global Sales Forecast (USD m) for Ixempra, 2013-2023 148

Table 43: Product Profile-Xeloda 149

Table 44: Xeloda SWOT Analysis, 2013 150

Table 45: AI Approvals in the US and 5EU 154

Table 46: Unmet Need and Opportunity in HER2-Negative Breast Cancer 158

Table 47: Product Profile-Abemaciclib (LY2835219) 172

Table 48: Abemaciclib SWOT Analysis, 2013 174

Table 49: Global Sales Forecast (USD m) for Abemaciclib, 2013-2023 175

Table 50: Product Profile-Buparlisib (BKM- 120) 177

Table 51: Buparlisib SWOT Analysis, 2013 179

Table 52: Global Sales Forecast (USD m) for Buparlisib, 2013-2023 180

Table 53: Product Profile-Javlor 182

Table 54: Javlor SWOT Analysis, 2013 184

Table 55: Global Sales Forecast (USD m) for Buparlisib, 2013-2023 185

Table 56: Product Profile-LEE011 187

Table 57: LEE011 SWOT Analysis, 2013 189

Table 58: Global Sales Forecast (USD m) for LEE011, 2013-2023 190

Table 59: Product Profile-NeuVax 192

Table 60: NeuVax SWOT Analysis, 2013 194

Table 61: Global Sales Forecast (USD m) for NeuVax, 2013-2023 195

Table 62: Product Profile-Niraparib 197

Table 63: Niraparib SWOT Analysis, 2013 199

Table 64: Global Sales Forecast (USD m) for Niraparib, 2013-2023 200

Table 65: Product Profile-NKTR- 102 201

Table 66: NKTR-102 SWOT Analysis, 2013 203

Table 67: Global Sales Forecast (USD m) for NKTR 102, 2013-2023 204

Table 68: Product Profile-Lynparza 206

Table 69: Lynparza SWOT Analysis, 2013 208

Table 70: Global Sales Forecast (USD m) for Lynparza, 2013-2023 209

Table 71: Product Profile-Palbociclib 211

Table 72: Palbociclib SWOT Analysis, 2013 213

Table 73: Global Sales Forecast (USD m) for Palbociclib, 2013-2023 215

Table 74: Product Profile-Talazoparib 217

Table 75: Talazoparib SWOT Analysis, 2013 218

Table 76 Global Sales Forecast (USD m) for Talazoparib, 2013-2023 219

Table 77: Product Profile-Veliparib 221

Table 78: Veliparib SWOT Analysis, 2013 223

Table 79: Global Sales Forecast (USD m) for Veliparib, 2013-2023 224

Table 80: Early-Stage Immunotherapies in Development for HER2-Negative Breast Cancer, 2014 225

Table 81: AstraZeneca's, Breast Cancer Portfolio Assessment, 2014 233

Table 82: AstraZeneca SWOT Analysis, 2014 233

Table 83: BMS' Breast Cancer Portfolio Assessment, 2014 235

Table 84: BMS SWOT Analysis, 2014 235

Table 85: Eli Lilly SWOT Analysis, 2014 236

Table 86: Pfizer's Breast Cancer Portfolio Assessment, 2014 238

Table 87: Pfizer SWOT Analysis, 2014 238

Table 88: Novartis' Breast Cancer Portfolio Assessment, 2014 240

Table 89: Novartis SWOT Analysis, 2014 240

Table 90: Global Sales Forecasts (USD m) for HER2-Negative Breast Cancer, 2013-2023 244

Table 91: Global HER2-Negative Breast Cancer Market-Drivers and Barriers, 2013-2023 247

Table 92: Sales Forecasts (USD m) for HER2-Negative Breast Cancer in the US, 2013-2023 250

Table 93: Key Events Impacting Sales for HER2-Negative Breast Cancer in the US, 2013-2023 252

Table 94: US HER2-Negative Breast Cancer Market-Drivers and Barriers, 2013-2023 253

Table 95: Sales Forecasts (USD m) for HER2-Negative Breast Cancer in France, 2013-2023 256

Table 96: Key Events Impacting Sales for HER2-Negative Breast Cancer in France, 2013-2023 258

Table 97: French HER2-Negative Breast Cancer Market-Drivers and Barriers, 2013-2023 259

Table 98: Sales Forecasts (USD m) for HER2-Negative Breast Cancer in Germany, 2013-2023 262

Table 99: Key Events Impacting Sales for HER2-Negative Breast Cancer in Germany, 2013-2023 264

Table 100: German HER2-Negative Breast Cancer Market-Drivers and Barriers, 2013-2023 265

Table 101: Sales Forecasts (USD m) for HER2-Negative Breast Cancer in Italy, 2013-2023 268

Table 102: Key Events Impacting Sales for HER2-Negative Breast Cancer in Italy, 2013-2023 270

Table 103: Italian HER2-Negative Breast Cancer Market-Drivers and Barriers, 2013-2023 271

Table 104: Sales Forecasts (USD m) for HER2-Negative Breast Cancer in Spain, 2013-2023 273

Table 105: Key Events Impacting Sales for HER2-Negative Breast Cancer in Spain, 2013-2023 275

Table 106: Spanish HER2-Negative Breast Cancer Market-Drivers and Barriers, 2013-2023 276

Table 107: Sales Forecasts (USD m) for HER2-Negative Breast Cancer in the UK, 2013-2023 279

Table 108: Key Events Impacting Sales for HER2-Negative Breast Cancer in the UK, 2013-2023 281

Table 109: UK HER2-Negative Breast Cancer Market-Drivers and Barriers, 2013-2023 282

Table 110: Sales Forecasts (USD m) for HER2-Negative Breast Cancer Japan, 2013-2023 285

Table 111: Key Events Impacting Sales for HER2-Negative Breast Cancer in Japan, 2013-2023 287

Table 112: Japanese HER2-Negative Breast Cancer Market-Drivers and Barriers, 2013-2023 288

Table 113: Sales Forecasts (USD m) for HER2-Negative Breast Cancer in China, 2013-2023 290

Table 114: Key Events Impacting Sales for HER2-Negative Breast Cancer in China, 2013-2023 292

Table 115: Chinese HER2-Negative Breast Cancer Market-Drivers and Barriers, 2013-2023 292

Table 116: HER2-Negative Breast Cancer Incidence, 2013-2023 330

Table 117: Key Launch Dates of Marketed and Pipeline Drugs for HER2-Negative Breast Cancer 331

Table 118: Key Expiry Dates of Marketed and Pipeline Drugs Used in HER2-Negative Breast Cancer 332

Table 119: Average Body Weight and Surface Area Across the 8MM 333

Table 120: Cost per Treatment Cycle (USD )-Abraxane, Metastatic Setting (HR+) 336

Table 121 Cost per Treatment Cycle (USD )-Avastin, Metastatic Setting (HR+/TNBC) 337

Table 122: Cost per Treatment Cycle (USD )-Afinitor, Third-Line Hormonal/ Targeted Therapy 338

Table 123: Cost per Treatment Cycle (USD )-Doxil, Metastatic Setting (HR+/TNBC) 339

Table 124: Cost per Treatment Cycle (USD )-Halaven, Metastatic Setting (HR+/TNBC) 340

Table 125: Cost per Treatment Cycle (USD )-Ixempra, Metastatic Setting (HR+/TNBC) 341

Table 126 Cost per Treatment Cycle (USD )-Xeloda, Metastatic Setting (HR+/TNBC) 342

Table 127: Cost per Treatment Cycle (USD )-Abemaciclib, First-/Second-Line Hormonal/Targeted Metastatic Setting (HR+) 343

Table 128: Cost per Treatment Cycle (USD )-Buparlisib, Postmenopausal Hormonal Neoadjuvant, Second- and Third-Line Hormonal/Targeted Metastatic Settings (HR+) 344

Table 129: Cost per Treatment Cycle (USD )-Javlor, Third-Line Chemotherapy Metastatic Setting (HR+) 345

Table 130: Cost per Treatment Cycle (USD )-LEE011, Postmenopausal Hormonal Neoadjuvan, and First-Line Hormonal/Targeted Metastatic Settings (HR+) 346

Table 131: Cost per Treatment Cycle (USD )-NeuVax, Adjuvant Setting (HR+) 347

Table 132: Cost per Treatment Cycle (USD )-Niraparib, Metastatic TNBC Setting 347

Table 133: Cost per Treatment Cycle (USD )-NKTR-102, Third Line Chemotherapy Metastatic Setting (HR+) 348

Table 134: Cost per Treatment Cycle (USD )-Lynparza, Adjuvant and First-Line Metastatic TNBC Settings 349

Table 135: Cost per Treatment Cycle (USD )-Palbociclib, First- and Second-Line Hormonal/Targeted Metasatatic Setting (HR+) 350

Table 136: Cost per Treatment Cycle (USD )-Talazoparib, Third-Line Metastatic TNBC Setting 351

Table 137: Cost per Treatment Cycle (USD )-Veliparib, Neoadjuvant and Second-Line Metastatic TNBC Settings 352

Table 138: Physicians Surveyed by Country 355

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AstraZeneca

Bristol-Myers Squibb

Eli Lilly

Pfizer

Novartis/GlaxoSmithKline


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com